Abstract
In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference73 articles.
1. Breast cancer treatment: A review;Waks;JAMA,2019
2. Schettini, F., Giuliano, M., Giudici, F., Conte, B., De Placido, P., Venturini, S., Rognoni, C., Di Leo, A., Locci, M., Jerusalem, G., Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers, 2021. 13.
3. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomized trials. Lancet, 2015. 386.
4. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patients-level meta-analysis of randomized trials;Davies;Lancet,2011
5. Results of the ATAC (Arimidex, Tamoxifen; Alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer;Howell;Lancet,2005
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献